Karina M Berge, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 16 years
- Graduated 2010
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Karina M Berge’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence C20223 · Cancelled
Licence status: Cancelled · since 1958 · Indiana University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$4,760
Medicare paid this office $4,760 for 32 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 21 | $2,634 | $105 |
| Return visit (30+ min) | 13 | $1,640 | $66 |
Who their Medicare patients are
32 Original Medicare patients in 2024. Average age 57 · Under 65 59% · Women 63% · Also on Medicaid 63% · Health risk score 1.51. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 59% · Heart failure 41% · Atrial fibrillation 38%.
The office billed $37,226, Medicare allowed $6,391 and paid $4,760; for 67 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 32 | 67 | 57 | 1.51 | $37,226 | $4,760 |
| 2023 | 27 | 73 | 57 | 1.80 | $39,598 | $5,075 |
| 2022 | 19 | 58 | 43 | 1.07 | $34,972 | $4,597 |
| 2021 | 15 | 30 | 42 | 1.67 | $20,770 | $2,702 |
| 2020 | 20 | 22 | 58 | 1.39 | $13,719 | $1,329 |
| 2019 | 33 | 43 | 55 | 1.76 | $32,078 | $3,087 |
| 2018 | 13 | 15 | 56 | 1.32 | $11,827 | $1,295 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 12 | $2,207 | $61 |
| Long return visit (40+ min) | 14 | $1,736 | $102 |
2020: 1 service
| Long return visit (40+ min) | 12 | $847 | $71 |
2019: 1 service
| Long return visit (40+ min) | 25 | $2,191 | $73 |
Drugs they prescribed that Part D paid
$912,605
Pharmacies billed $912,605 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 654) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
482 generic and 172 brand-name prescriptions · $912,605 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Opsumit | 42 | $511,467 | $12,178 |
| Adcirca | 11 | $47,330 | $4,303 |
| Eliquis | 33 | $36,948 | $1,120 |
| Tadalafil | 21 | $35,611 | $1,696 |
| Xarelto | 17 | $24,793 | $1,458 |
See all 19 drugs
| Opsumit | 42 | $511,467 | $12,178 |
| Adcirca | 11 | $47,330 | $4,303 |
| Eliquis | 33 | $36,948 | $1,120 |
| Tadalafil | 21 | $35,611 | $1,696 |
| Xarelto | 17 | $24,793 | $1,458 |
| Farxiga | 19 | $18,079 | $952 |
| Entresto | 18 | $11,924 | $662 |
| Jardiance | 11 | $11,046 | $1,004 |
| Sildenafil Citrate | 30 | $8,552 | $285 |
| Metoprolol | 89 | $1,926 | $22 |
| Nifedipine Er | 19 | $726 | $38 |
| Potassium Chloride | 27 | $653 | $24 |
| Losartan | 21 | $352 | $17 |
| Atorvastatin | 29 | $321 | $11 |
| Spironolactone | 31 | $262 | $8 |
| Furosemide | 35 | $133 | $4 |
| Clopidogrel | 14 | $110 | $8 |
| Lisinopril | 22 | $41 | $2 |
| Amoxicillin | 13 | $10 | $1 |
Year by year
| 2024 | 654 | 78 | 0% (0) | 26% | $912,605 |
| 2023 | 617 | 81 | 0% (0) | 26% | $1,120,333 |
| 2022 | 617 | 88 | 0% (0) | None | $1,002,689 |
| 2021 | 574 | 77 | 0% (0) | 29% | $710,420 |
| 2020 | 488 | 60 | 0% (0) | 32% | $519,893 |
| 2019 | 286 | 50 | 0% (0) | 33% | $191,928 |
| 2018 | 61 | 21 | None | None | $1,304 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Opsumit | 47 | $597,036 | $12,703 |
| Uptravi | 11 | $294,088 | $26,735 |
| Eliquis | 21 | $35,236 | $1,678 |
| Sildenafil Citrate | 37 | $29,482 | $797 |
| Entresto | 34 | $25,204 | $741 |
| Xarelto | 11 | $18,096 | $1,645 |
| Nebivolol | 16 | $2,573 | $161 |
| Metoprolol | 71 | $1,502 | $21 |
| Atorvastatin | 44 | $1,132 | $26 |
| Losartan | 29 | $631 | $22 |
| Furosemide | 25 | $626 | $25 |
| Potassium Chloride | 15 | $607 | $40 |
| Spironolactone | 25 | $566 | $23 |
| Clopidogrel | 11 | $362 | $33 |
| Digoxin | 12 | $326 | $27 |
| Lisinopril | 20 | $276 | $14 |
| Nifedipine Er | 11 | $272 | $25 |
| Warfarin | 15 | $196 | $13 |
| Metoprolol | 11 | $117 | $11 |
| Prednisone | 11 | $69 | $6 |
| Amoxicillin | 14 | $20 | $1 |
2022: 18 drugs
| Opsumit | 47 | $549,064 | $11,682 |
| Adcirca | 11 | $49,542 | $4,504 |
| Eliquis | 28 | $36,025 | $1,287 |
| Entresto | 24 | $16,230 | $676 |
| Sildenafil Citrate | 30 | $3,691 | $123 |
| Metoprolol | 79 | $1,443 | $18 |
| Losartan | 50 | $788 | $16 |
| Digoxin | 14 | $747 | $53 |
| Atorvastatin | 41 | $643 | $16 |
| Furosemide | 28 | $545 | $19 |
| Spironolactone | 26 | $422 | $16 |
| Potassium Chloride | 19 | $398 | $21 |
| Carvedilol | 14 | $353 | $25 |
| Torsemide | 14 | $292 | $21 |
| Clopidogrel | 11 | $216 | $20 |
| Lisinopril | 18 | $192 | $11 |
| Metoprolol | 27 | $150 | $6 |
| Amoxicillin | 18 | $30 | $2 |
2021: 15 drugs
| Opsumit | 39 | $429,695 | $11,018 |
| Adcirca | 12 | $53,118 | $4,427 |
| Eliquis | 38 | $40,426 | $1,064 |
| Entresto | 15 | $9,195 | $613 |
| Metoprolol | 104 | $1,601 | $15 |
| Sildenafil Citrate | 17 | $1,155 | $68 |
| Bisoprolol | 11 | $910 | $83 |
| Atorvastatin | 32 | $470 | $15 |
| Potassium Chloride | 15 | $338 | $23 |
| Losartan | 31 | $319 | $10 |
| Spironolactone | 28 | $299 | $11 |
| Furosemide | 38 | $176 | $5 |
| Carvedilol | 13 | $172 | $13 |
| Metoprolol | 27 | $119 | $4 |
| Lisinopril | 19 | $109 | $6 |
2020: 16 drugs
| Opsumit | 40 | $415,988 | $10,400 |
| Adcirca | 12 | $51,767 | $4,314 |
| Eliquis | 17 | $16,860 | $992 |
| Xarelto | 16 | $12,266 | $767 |
| Metoprolol | 54 | $1,576 | $29 |
| Sildenafil Citrate | 20 | $1,292 | $65 |
| Valsartan | 19 | $953 | $50 |
| Furosemide | 48 | $395 | $8 |
| Atorvastatin | 20 | $299 | $15 |
| Potassium Chloride | 15 | $265 | $18 |
| Spironolactone | 18 | $254 | $14 |
| Losartan | 16 | $207 | $13 |
| Lisinopril | 13 | $166 | $13 |
| Warfarin | 18 | $153 | $9 |
| Metoprolol | 21 | $140 | $7 |
| Clopidogrel | 13 | $51 | $4 |
2019: 7 drugs
| Opsumit | 14 | $132,337 | $9,453 |
| Sildenafil Citrate | 20 | $1,147 | $57 |
| Metoprolol | 22 | $867 | $39 |
| Furosemide | 41 | $371 | $9 |
| Torsemide | 11 | $276 | $25 |
| Warfarin | 13 | $267 | $21 |
| Spironolactone | 15 | $237 | $16 |
2018: 2 drugs
| Metoprolol | 11 | $389 | $35 |
| Furosemide | 12 | $59 | $5 |
Money from drug and device companies
$187 in 2025
| 2025 | 2 | 2 | None | $187 |
| 2024 | 1 | 2 | None | $92 |
| 2023 | 1 | 1 | None | $89 |
| 2021 | 1 | 1 | None | $23 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Actelion Pharmaceuticals US | Uptravi | $142 | 1 payment
|
| Merck Sharp & Dohme | None | $45 | 1 payment
|
See all 2 published payments
| Merck Sharp & Dohme | Meals · 2025-08-19 | None | $45 |
| Actelion Pharmaceuticals US | Meals · 2025-01-14 | Uptravi | $142 |
See earlier years (2024, 2023, 2021)
2024: $92
| Merck Sharp & Dohme | None | $92 | 2 payments
|
2023: $89
| Merck Sharp & Dohme | None | $89 | 1 payment
|
2021: $23
| Actelion Pharmaceuticals US | Opsumit | $23 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285939553
- Licence
- CA 20223California C20223: Cancelled
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 2315 Stockton Blvd, Suite 6220, Sacramento, CA, 95817
- NPI first listed
- 2011-01-18
- NPI last updated
- 2013-07-29
This is when the NPI record was last certified, not a medical board exam.